Boiron (FRA:BON) Additional Paid-In Capital : €79.9 Mil(As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Boiron Additional Paid-In Capital?

Boiron's quarterly additional paid-in capital stayed the same from Dec. 2022 (€79.9 Mil) to Jun. 2023 (€79.9 Mil) and stayed the same from Jun. 2023 (€79.9 Mil) to Dec. 2023 (€79.9 Mil).

Boiron's annual additional paid-in capital stayed the same from Dec. 2021 (€79.9 Mil) to Dec. 2022 (€79.9 Mil) and stayed the same from Dec. 2022 (€79.9 Mil) to Dec. 2023 (€79.9 Mil).

Boiron Additional Paid-In Capital Historical Data

The historical data trend for Boiron's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boiron Additional Paid-In Capital Chart

Boiron Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

79.88

Boiron Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															79.88	79.88	79.88	79.88	79.88

Boiron Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Boiron Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Boiron's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Boiron (FRA:BON) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Boiron SA (FRA:BON) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

BOIRF:USA BOI:France BON:Germany

Address

2, Avenue de l’Ouest Lyonnais No. 039, Messimy, FRA, 69510

Website

http://www.boiron.com

Boiron is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.